临床IA期原发性肺癌伴隐匿性N2病变:肺叶切除与亚肺叶切除的比较
本研究利用美国国家癌症数据库2010至2017年数据,比较临床IA期非小细胞肺癌最终病理为N2病变患者行亚肺叶切除与肺叶切除的生存差异。共纳入2419例患者,其中亚肺叶切除320例(13.2%),肺叶切除2099例(86.8%)。亚肺叶切除与肺叶切除相比,单因素及多因素分析均未显示生存更差。
要点
- 临床IA期非小细胞肺癌最终病理N2患者中,亚肺叶切除占13.2%(320/2419)。
- 亚肺叶切除与肺叶切除的5年生存率分别为46.6%和45.2%,差异无统计学意义(P=0.319)。
- 多因素Cox分析风险比为0.97(P=0.789),亚肺叶切除未显示生存更差。
核心结论
- 临床IA期非小细胞肺癌最终病理为N2病变的患者,亚肺叶切除与肺叶切除的长期生存相似。
- 亚肺叶切除后发现有隐匿性N2病变的患者可能不需要再次手术行完成性肺叶切除,而应接受辅助化疗。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库2010至2017年数据。
- 纳入接受原发手术切除的临床IA期非小细胞肺癌且病理为N2病变的患者,共2419例。
- 亚肺叶切除320例(13.2%),肺叶切除2099例(86.8%)。
- 采用logistic回归评估亚肺叶切除的使用,Kaplan-Meier分析、log-rank检验和Cox比例风险模型评估生存。
主要发现
- 亚肺叶切除组与肺叶切除组相比,年龄更大、女性更多、肿瘤更小及在学术机构治疗预测亚肺叶切除的使用。
- 肺叶切除组肿瘤更大(2.40 vs 2.05 cm,P < 0.001),检查淋巴结更多(11 vs 5,P < 0.001)。
- 辅助化疗使用两组相似(亚肺叶切除79.4% vs 肺叶切除77.4%,P = 0.434)。
- 单因素分析5年生存率亚肺叶切除46.6% vs 肺叶切除45.2%(P = 0.319)。
- 多因素Cox分析风险比0.97(P = 0.789)。
临床怎么用
- 作者认为,亚肺叶切除后发现有隐匿性N2病变的患者可能不需要再次手术行完成性肺叶切除,而应接受辅助化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Sublobar resection is increasingly being utilized for early-stage lung cancers, but optimal management when final pathology shows unsuspected mediastinal nodal disease is unclear. This study tested the hypothesis that lobectomy has improved survival compared to sublobar resection for clinical stage IA tumours with occult N2 disease. METHODS: The use of sublobar resection and lobectomy for patients in the National Cancer Database who underwent primary surgical resection for clinical stage IA non-small-cell lung cancer with pathologic N2 disease between 2010 and 2017 was evaluated using logistic regression. Survival was assessed with Kaplan-Meier analysis, log-rank test and Cox proportional hazards model. RESULTS: A total of 2419 patients comprised the study cohort, including 320 sublobar resections (13.2%) and 2099 lobectomies (86.8%). Older age, female sex, smaller tumour size and treatment at an academic facility predicted the use of sublobar resection. Patients undergoing lobectomy had larger tumours (2.40 vs 2.05 cm, P < 0.001) and more lymph nodes examined (11 vs 5, P < 0.001). Adjuvant chemotherapy use was similar between the 2 groups (sublobar 79.4% vs lobectomy 77.4%, P = 0.434). Sublobar resection was not associated with worse survival compared to lobectomy in both univariate (5-year survival 46.6% vs 45.2%, P = 0.319) and multivariable Cox proportional hazards analysis (hazard ratio 0.97, P = 0.789). CONCLUSIONS: Clinical stage IA non-small-cell lung cancer patients with N2 disease on final pathology have similar long-term survival with either sublobar resection or lobectomy. Patients with occult N2 disease after sublobar resection may not require reoperation for completion lobectomy but should instead proceed to adjuvant chemotherapy.
引用
- Liou DZ, Chan M, Bhandari P, et al. Lobar versus sublobar resection in clinical stage IA primary lung cancer with occult N2 disease. Eur J Cardiothorac Surg. 2022. PMID: 36063054. doi:10.1093/ejcts/ezac440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。